Search our team at AdventHealth Research Institute
-
NCT05865535
AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe study involves research. The purpose of the study is to see if a single dose and multiple doses of the study drug, AV 380, are safe and tolerated in cancer participants. This study will also help...
-
NCT04956640
LOXO-RAS-20001: A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main purpose of this research study (during both monotherapy and combination therapy evaluation) includes the following: To determine whether LY3537982 is safe; To identify which dose level of...
-
NCT04427384
A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
This study is currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research is to evaluate real-world clinical outcomes and patient-reported
outcomes that measure the effectiveness and safety of GammaTiles, which is the type of
radiation therapy... -
NCT05346835
68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05948865
CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into...
-
NCT05822752
M24-147: A Phase 2, Randomized Open-Label Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine the optimal dose of livmoniplimab and to determine if livmoniplimab in combination with budigalimab is safe and effective at treating locally advanced or...
-
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT05671510
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer ResearchThe main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care...
-
NCT04637763
CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaAllogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR...
-
Childhood Sjogren Disease Long Term Outcomes
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research is to describe the natural history of children diagnosed with, or suspected of being at risk for development of, childhood Sjogren Disease. This is a critically...
-
NCT04561362
BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, Florida -
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...